Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial

Purpose

This phase II trial compares standard of care surgical resection to fluorescence-guided surgical resection using indocyanine green and fluorescence imaging for reducing unexpected positive margin rates in patients with sarcoma. Surgical margins are one of the criteria used in assessing the effectiveness of a given surgical procedure. They are the edges or border of the tissue removed in cancer surgery. A negative margin means that the resected tumor is surrounded by normal tissue, which implies there is no disease left in the patient. By contrast, a positive margin means that sarcoma cells are visible at the edge of the tumor. Positive margins may be classified as planned when they are expected pre-operatively due to the preservation of a critical structure, or unexpected when the pathologist reports the presence of tumor at the margin despite the surgeon having intended to remove it in its entirety. Fluorescence-guided surgery is an established surgical method that involves the administration of fluorescent dye (in this case, indocyanine green) into the tumor, which can then be visualized with a special camera during surgery to help surgeons identify tumor versus healthy tissue. Fluorescence-guided surgery may reduce the rate of unexpected positive margins in patients undergoing surgery for sarcoma.

Conditions

  • High Grade Sarcoma
  • Sarcoma

Eligibility

Eligible Ages
All ages
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Documented written informed consent of the participant - Histologically confirmed diagnosis of intermediate to high grade sarcoma - All ages - Amenable to surgical resection as a part of curative intent for the patient - Willingness to: - Respond to surveys during the trial - Permit medical record/ clinical laboratory result review

Exclusion Criteria

  • Due for surgery with palliative intent - Recurrent tumors - Intracranial, retroperitoneal, and visceral anatomical locations - A woman of childbearing potential who is currently pregnant (as confirmed by urine pregnancy test) - A woman who are currently breastfeeding - Known allergies to ICG, iodine, iodine dyes or shellfish - Unable to provide written and informed consent - Patients with hyper-thyroidism or autonomic thyroid adenomas - Premature infants/neonates with exchange transfusion indication due to hyperbilirubinemia

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)
Masking Description
The histopathology staff and senior trial statistician will be blinded and unaware of the surgery type to allow for blinded measurement and analysis of primary outcome.

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Arm I (standard of care) 		Patients undergo standard of care surgical resection.
  • Other: Electronic Health Record Review
    Ancillary studies
  • Other: Questionnaire Administration
    Ancillary studies
  • Procedure: Resection
    Undergo surgical resection
    Other names:
    • Surgical Resection
Experimental
Arm II (FGS) 		Patients receive ICG IV 12-24 hours prior to their scheduled surgery. Patients then undergo FGS with intraoperative fluorescence imaging.
  • Other: Electronic Health Record Review
    Ancillary studies
  • Procedure: Fluorescence Imaging
    Undergo fluorescence imaging
  • Procedure: Fluorescence-Guided Surgery
    Undergo FGS
    Other names:
    • FGS
    • Fluorescence-Guided Surgical Procedure
  • Drug: Indocyanine Green
    Given IV
    Other names:
    • ICG
  • Other: Questionnaire Administration
    Ancillary studies

Recruiting Locations

City of Hope Medical Center
Duarte, California 91010
Contact:
Thinzar Lwin
626-218-3880
tlwin@coh.org

More Details

Status
Recruiting
Sponsor
City of Hope Medical Center

Study Contact

Detailed Description

PRIMARY OBJECTIVE: I. To determine whether there is a reduction in the unexpected positive margin rate (UPM) in patients receiving fluorescence-guided surgery (FGS) using indocyanine green (ICG) compared to standard of care (SoC). SECONDARY OBJECTIVE: I. To determine the effect of FGS using ICG compared to the SoC over a 12-month period. EXPLORATORY OBJECTIVE: I. To determine the role of ICG in the pathological margin assessment of resected sarcoma specimens whilst improving understanding of the cellular mechanisms of FGS using ICG. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo standard of care surgical resection. ARM II: Patients receive ICG intravenously (IV) 12-24 hours prior to their scheduled surgery. Patients then undergo FGS with intraoperative fluorescence imaging. After completion of study treatment, patients are followed up at 1, 3, 6, and 12 months.